2024-09-16 - Analysis Report
##  ABT Stock Analysis Report 

**Company Overview:** Abbott Laboratories (ABT) is a global healthcare company that develops, manufactures, and markets a wide range of healthcare products, including pharmaceuticals, medical devices, diagnostics, and nutritionals. 

**1. Performance Analysis:**

ABT's cumulative return of 45.62% lags behind the S&P 500 (VOO) at 88.73%, resulting in a negative divergence of -43.11%. This signifies that ABT's performance has been weaker than the broader market over the given period. The relative divergence of 19.88% indicates that ABT's current performance ranks in the 19.88th percentile of its historical range. 

**2. Recent Price Movement:**

* **Closing Price:** $116.4
* **5-day Moving Average:** $116.67
* **20-day Moving Average:** $113.7
* **60-day Moving Average:** $108.3

ABT's current price is above its 5-day and 20-day moving averages, indicating a potential short-term uptrend. However, the price is below the 60-day moving average, which could suggest some longer-term resistance.

**3. Technical Indicators:**

* **RSI:** 69.76
* **PPO:** 0.1
* **Delta_Previous_Relative_Divergence:** 4.37 (+)
* **Expected_Return:** 25.51%

The RSI of 69.76 indicates that ABT is in overbought territory, suggesting potential for a short-term pullback.  The PPO of 0.1 shows a positive momentum, indicating a potential for continued upward movement. The positive Delta_Previous_Relative_Divergence signifies a short-term upward trend, indicating potential for further price gains. The expected return of 25.51% suggests a positive outlook for the stock over the next five years.

**4. Recent Earnings and Outlook:**

| Date | EPS | Revenue |
|---|---|---|
| 2024-07-31 | 0.74 | 10.38 B$ |
| 2024-05-02 | 0.7 | 9.96 B$ |
| 2023-11-01 | 0.82 | 10.14 B$ |
| 2023-08-03 | 0.79 | 9.98 B$ |
| 2024-07-31 | 0.79 | 9.98 B$ |

ABT's most recent earnings report for Q2 2024 exceeded analysts' expectations, with EPS coming in at $0.74 against an estimate of $0.70. Revenue also exceeded expectations, reaching $10.38 billion compared to the anticipated $10.20 billion. These results demonstrate ABT's consistent revenue growth and earnings performance.


**5. Summary:**

ABT's performance has lagged behind the broader market in the past but is showing signs of potential recovery based on recent price action and earnings results. The stock is currently overbought, but technical indicators suggest potential for further short-term gains. The strong earnings performance and positive outlook make ABT an interesting investment opportunity for investors looking for exposure to the healthcare sector.  

**6. Recommendations:**

Given the current overbought conditions and the fact that ABT's performance has lagged behind the market, it is recommended to exercise caution when investing in this stock. Investors may consider waiting for a potential pullback before entering a position, or focusing on accumulating shares gradually over time through a dollar-cost averaging strategy. However, ABT's strong earnings performance and positive outlook make it an attractive long-term investment opportunity for investors with a high risk tolerance.
